Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021)
Harmony Biosciences Holdings (HRMY) posted Non-Current Deffered Revenue of $192000.0 for Q1 2021, down 9.43% sequentially from $212000.0 in Q4 2020.
Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends
Harmony Biosciences Holdings has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $192000.0 in Q1 2021.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $192000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $192000.0 (changed N/A YoY) and the FY2020 annual result came in at $212000.0, down 26.13% from the prior year.
- Non-Current Deffered Revenue declined to $192000.0 in Q1 2021 per HRMY's latest filing, from $212000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $305000.0 in Q3 2020 and troughed at $192000.0 in Q1 2021.
- A 3-year average of $249000.0 and a median of $249500.0 in 2019 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 26.13% in 2020, down 26.13% in 2020.
- Over 3 years, Non-Current Deffered Revenue stood at $287000.0 in 2019, then fell by 26.13% to $212000.0 in 2020, then slipped by 9.43% to $192000.0 in 2021.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $192000.0, $212000.0, and $305000.0 for Q1 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 192,000.00 |
| Dec 31, 2020 | 212,000.00 |
| Sep 30, 2020 | 305,000.00 |
| Dec 31, 2019 | 287,000.00 |